Consensus Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Real-time Estimate Cboe BZX Other stock markets 12:33:42 2024-04-25 pm EDT			5-day change	1st Jan Change
0.488 ^USD	-1.01%		+0.31%	-10.44%

Mar. 22	Sangamo Therapeutics Prices $24 Million Registered Direct Offering	MT
Mar. 14	Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	MT

Evolution of the average Target Price on Sangamo Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

dc0421b206bfbf9de23ed2e88.WIBPACJ5oUsrB1Q5swOl1I9gt-ReDKVjUo2RzFNPL9Q.bvg_cVQd9yZyYTVYxHHgguFVx45qPdwJZL2iugsXfudhy39NVBHlAUlzDQ~d42431c765d6426d99c92717e1539913

Analyst Recommendations on Sangamo Therapeutics, Inc.

Truist Securities Downgrades Sangamo Therapeutics to Hold From Buy	Nov. 07	MT
HC Wainwright Cuts Price Target on Sangamo Therapeutics to $3 From $5, Maintains Buy Rating	Nov. 06	MT
Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight From Overweight, Price Target is $1	Nov. 06	MT
Wedbush Lowers Sangamo Therapeutics' PT to $2 From $10 as Result of Valuing Potential Royalty From ST-920 Sales, Keeps Outperform Rating	Nov. 03	MT
RBC Downgrades Sangamo Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Cites 'Cash Preservation Mode,' Keeps Speculative Risk	Nov. 03	MT
Truist Securities Adjusts Price Target on Sangamo Therapeutics to $7 From $8, Maintains Buy Rating	23-08-15	MT
Wedbush Lowers Sangamo Therapeutics' Price Target to $10 From $16, Keeps Outperform Rating	23-08-11	MT
Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $4 From $5, Maintains Overweight Rating	23-08-10	MT
Barclays Lowers Sangamo Therapeutics' Price Target to $9 From $11, Overweight Rating Maintained	23-08-09	MT
RBC Cuts Price Target on Sangamo Therapeutics to $6 From $8, Keeps Outperform, Speculative Risk	23-08-09	MT
Truist Adjusts Price Target on Sangamo Therapeutics to $8 From $16, Keeps Buy Rating	23-05-10	MT
HC Wainwright Adjusts Sangamo Therapeutics' Price Target to $5 From $15, Keeps Buy Rating	23-05-01	MT
RBC Capital Adjusts Sangamo Therapeutics Price Target to $8 From $13, Maintains Outperform - Speculative Risk Rating	23-04-06	MT
HC Wainwright Adjusts Sangamo Therapeutics Price Target to $15 From $25, Maintains Buy Rating	23-03-03	MT
Wedbush Upgrades Sangamo Therapeutics to Outperform From Neutral, Raises Price Target to $16 From $4	23-02-27	MT
RBC Capital Adjusts Price Target on Sangamo Therapeutics to $13 From $22, Maintains Outperform Rating	23-02-23	MT
Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $15 From $20, Maintains Overweight Rating	23-01-04	MT
Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $20 From $22, Maintains Overweight Rating	22-11-07	MT
Wedbush Adjusts Sangamo Therapeutics' Price Target to $4 From $5 After Increase in Share Count, Keeps Neutral Rating	22-11-07	MT
Truist Trims Price Target for Sangamo Therapeutics to $17 From $19, Maintains Buy Rating	22-08-08	MT
Wedbush Analyst Assumes Coverage of Neutral-Rated Sangamo Therapeutics, Adjusts Price Target to $5 From $10, Notes 'Uncertainty Around' SAR445136 Path Forward in Sickle Cell Disease	22-06-13	MT
Truist Lowers Price Target for Sangamo Therapeutics to $19 From $23, Maintains Buy Rating	22-04-04	MT
Wedbush Trims Price Target for Sangamo Therapeutics to $10 From $11 as Collaboration with Sanofi on BIVV003 Ends, Keeps Neutral Rating	22-01-07	MT
Stifel Nicolaus Adjusts Sangamo Therapeutics Price Target to $6 From $9, Maintains Hold Rating	22-01-06	MT
SANGAMO THERAPEUTICS : RBC Initiates Sangamo Therapeutics at Outperform-Speculative Risk, Starts Price Target at $22	21-05-04	MT